title: [Henoch-schönlein purpura induced by erlotinib (Tarceva): a case report].
abstract: Erlotinib is a newly developed molecular-targeting or molecular-targeted drug with selective inhibitory activity for tyrosine kinase of the epidermal growth factor receptor. A adverse drug reactions including diarrhea, skin eruptions are considered mild. We report a case of recurrent adenocarcinoma of the lung in a 68-year-old woman who suffered from Henoch-Schönlein purpura induced by erlotinib. She received daily administration of erlotinib 150 mg as second-line chemotherapy. Her tumors decreased in size and pleural effusion disappeared, so we considered erlotinib effective. However after 3 months of treatment with erlotinib, the patient presented palpable purpuric lesions mostly located on her lower legs. We diagnosed Henoch-Schönlein purpura based on skin histological findings. Erlotinib was reduced but continued, with improvement of the eruptions. Henoch-Schönlein purpura is often accompanied by systemic manifestations, such as renal disease and arthritis, so more careful follow-up is warranted.
authors.affiliation: Internal Medicine, Social Insurance Kyoto Hospital.
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Yuba
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Nagata
authors.forename: Shinsuke
authors.initials: S
authors.lastname: Shiotsu
authors.forename: Akira
authors.initials: A
authors.lastname: Okano
authors.forename: Mayumi
authors.initials: M
authors.lastname: Hatsuse
authors.forename: Satoshi
authors.initials: S
authors.lastname: Murakami
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Morihara
authors.forename: Chihiro
authors.initials: C
authors.lastname: Shimazaki
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy; D000368:Aged; D000069347:Erlotinib Hydrochloride; D005260:Female; D006801:Humans; D011695:IgA Vasculitis / Q000139:chemically induced*; D008175:Lung Neoplasms / Q000188:drug therapy; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011799:Quinazolines / Q000009:adverse effects*
chemical_list: D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride